Gemcitabine elaidate

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug NameGemcitabine elaidate
Drug Alias NameGemcitabine 5'-elaidic acid ester吉西他滨油酸酯CO-101CO-1.01CP-4126
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionDNA synthesis inhibitors
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[15] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAqualis
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesClavis PharmaClovis Oncology Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A